Besides MDS/AML, a pan-cancer analysis of TP53 mutations and related metabolic pathways showed that TP53 plays a key role in glycolysis regulation by suppressing the AKT/mTOR and NF-kB signaling pathways and the expression of related genes, such as PFKP and SLC16A3 [24]. The gene discussed is TP53; the disease is acute myeloid leukemia.